Thrombotic episodes in superficial venous malformations in children
Conditions
Brief summary
Evaluation of the efficacy on pain of acetylsalicylic acid + local NSAID versus placebo + local NSAID, administered for a period of 3 days to 14 days
Detailed description
Cumulative consumption of tier 1 and 2 analgesics (indirect reflection of treatment efficacy) over 14 days, Impact on the child's quality of life (by measuring the C-DLQI - Children-Quality of Life Index and the CLFMQol - specific Quality Of Life measurement tool for Children with Low-Flow Malformations) at baseline, and after each attack, Safety: number of serious and non-serious adverse events in each group, Comparison of the impact of experimental treatment and control treatment on coagulation markers during attacks of superficial venous thrombosis in superficial venous malformations, by measuring : CBC, PT, APTT, plasma fibrinogen and D-dimers, Impact of the malformation on sleep quality (Fast Score SLEEP VASC) measured once a day for 14 days, Functional impairment related to the malformation will be assessed daily using a VAS (visual analog scale, ranging from 0 to 10) (0 no discomfort, 10 maximum discomfort, inability to move a limb or body segment) at baseline and after each follow-up.
Interventions
DRUGASPRO 320 mg
DRUGcomprimé
DRUGCALCIUM HYDROGEN PHOSPHATE DIHYDRATE
DRUGDICLOFENAC ARROW 1 %
DRUGgel en flacon pressurisé
Sponsors
Centre Hospitalier Regional Universitaire De Tours
Eligibility
Sex/Gender
All
Age
0 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the efficacy on pain of acetylsalicylic acid + local NSAID versus placebo + local NSAID, administered for a period of 3 days to 14 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative consumption of tier 1 and 2 analgesics (indirect reflection of treatment efficacy) over 14 days, Impact on the child's quality of life (by measuring the C-DLQI - Children-Quality of Life Index and the CLFMQol - specific Quality Of Life measurement tool for Children with Low-Flow Malformations) at baseline, and after each attack, Safety: number of serious and non-serious adverse events in each group, Comparison of the impact of experimental treatment and control treatment on coagulation markers during attacks of superficial venous thrombosis in superficial venous malformations, by measuring : CBC, PT, APTT, plasma fibrinogen and D-dimers, Impact of the malformation on sleep quality (Fast Score SLEEP VASC) measured once a day for 14 days, Functional impairment related to the malformation will be assessed daily using a VAS (visual analog scale, ranging from 0 to 10) (0 no discomfort, 10 maximum discomfort, inability to move a limb or body segment) at baseline and after each fol | — |
Outcome results
None listed